X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Partnership will support the n-Lorem’s effort to discover and provide experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients (1 to 30 patients worldwide) for free, for life.
Lead Product(s): Antisense Oligonucleotide
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: n-Lorem Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 23, 2022
Details:
The phase 1c/2a trial MF‐101 aims to demonstrate that PXS‐5505 is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs.
Lead Product(s): PXS-5505
Therapeutic Area: Oncology Product Name: PXS-5505
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Pharmaxis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2021
Details:
CONCLUDE is a randomised, double-blind, placebo-controlled, global phase III study to evaluate cobitolimod as a novel treatment for patients with moderate to severe left-sided ulcerative colitis.
Lead Product(s): Cobitolimod
Therapeutic Area: Gastroenterology Product Name: Kappaproct
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: InDex Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 30, 2021
Details:
This clinical study will evaluate the safety, tolerability, and clinical activity of escalating doses of orally administered capsules of Foralumab. The trial is a dose-ranging, open-label study that will enroll 60 patients in the U.S. and Europe.
Lead Product(s): Foralumab
Therapeutic Area: Gastroenterology Product Name: TZLS-401
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Tiziana Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 11, 2020
Details:
Synairgen’s study will evaluate the ability of SNG001, an inhaled formulation of IFN-beta-1a, to accelerate recovery among hospitalized patients receiving oxygen.
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: SNG001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Synairgen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
